TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Investment analysts at HC Wainwright dropped their Q3 2024 earnings estimates for shares of TransCode Therapeutics in a research note issued to investors on Thursday, August 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.51) for the quarter, down from their previous forecast of ($0.35). HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($1.98) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($2.05) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.30) EPS and FY2028 earnings at ($0.25) EPS.
TransCode Therapeutics Price Performance
Shares of TransCode Therapeutics stock opened at $0.27 on Monday. The company has a 50 day moving average price of $0.69 and a 200 day moving average price of $0.78. TransCode Therapeutics has a 52 week low of $0.22 and a 52 week high of $128.00.
Hedge Funds Weigh In On TransCode Therapeutics
About TransCode Therapeutics
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Read More
- Five stocks we like better than TransCode Therapeutics
- 3 REITs to Buy and Hold for the Long Term
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 2 Option Strategies to Maximize Profits in a Bear Market
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.